Lung CancerPhase 3NCT00045162
S0124: Cisplatin Combined With Irinotecan or Etoposide For Extensive-Stage Small Cell Lung Cancer
A Phase 3 study testing cisplatin, etoposide and irinotecan hydrochloride in people with Lung Cancer, run by SWOG Cancer Research Network at 408 sites in 2 countries.
Trial summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known whether cisplatin combined with irinotecan is more effective than cisplatin combined with etoposide in treating… Read more about this study
- Who is it for?
- Ages 18 to 120 years
- Conditions the study is for
- Lung Cancer
- What is being tested?
- cisplatin, etoposide and irinotecan hydrochloride
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 671 participants
- Where
- 408 sitesin 2 countries
- Study dates
- Nov 2002to Dec 2009
- Phase
- Phase 3
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 120 years
- All sexes
- No healthy volunteers
- Adult, Older adult
DISEASE CHARACTERISTICS:
- Histologically or cytologically confirmed extensive stage small cell lung cancer (SCLC)
- Measurable or evaluable disease by CT scan, MRI, x-ray, physical exam, or nuclear exam
- Brain metastases allowed if previously treated with radiotherapy and/or surgery and are neurologically stable (i.e., no progressing symptoms and off steroids and anticonvulsants)
PATIENT CHARACTERISTICS:
Age
- 18 and over
Performance status
- Zubrod 0-1
Life expectancy
- Not specified
Hematopoietic
- WBC at least 3,000/mm^3
- Absolute granulocyte count at least 1,500/mm^3
- Platelet count at least 100,000/mm^3
Hepatic
- Bilirubin no greater than 1.5 times upper limit of normal (ULN)
- AST or ALT no greater than 2.5 times ULN
Renal
- Creatinine normal
- Creatinine clearance at least 50 mL/min
Other
- Not pregnant or nursing
- Fertile patients must use effective contraception
- No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix
- HIV negative
- No concurrent AIDS-related illness
PRIOR CONCURRENT THERAPY:
Biologic therapy
- No prior biologic therapy for SCLC
- No filgrastim (G-CSF) within 24 hours of chemotherapy
Chemotherapy
- No prior systemic chemotherapy for SCLC
Endocrine therapy
- See Disease Characteristics
Radiotherapy
- See Disease Characteristics
- At least 21 days since prior brain radiotherapy and recovered
- No other prior radiotherapy for SCLC
Surgery
- See Disease Characteristics
- At least 21 days since prior thoracic or other major surgery and recovered
Other
- No concurrent enzyme inducing antiepileptic drugs (phenytoin, phenobarbital, oxcarboxepine, or carbamazepine)
Trial locations and contacts
408 sites in 2 countries.
302 sites in 2 countries
United States300 sites
Hickman Cancer Center at Bixby Medical Center
Adrian, Michigan, 49221
McDowell Cancer Center at Akron General Medical Center
Akron, Ohio, 44307
Tulane Cancer Center
Alexandria, Louisiana, 71315-3198
Study site
Alexandria, Minnesota, 56308
Morgan Cancer Center at Lehigh Valley Hospital - Cedar Crest
Allentown, Pennsylvania, 18105
Saint Anthony's Hospital at Saint Anthony's Health Center
Alton, Illinois, 62002
American Fork Hospital
American Fork, Utah, 84003
Alaska Regional Hospital Cancer Center
Anchorage, Alaska, 99508
AnMed Cancer Center
Anderson, South Carolina, 29621
Saint Joseph Mercy Cancer Center
Ann Arbor, Michigan, 48106-0995
CCOP - Michigan Cancer Research Consortium
Ann Arbor, Michigan, 48106
Northeast Alabama Regional Medical Center
Anniston, Alabama, 36202
Fox Valley Hematology and Oncology - East Grant Street
Appleton, Wisconsin, 54911-3496
Piedmont Hospital
Atlanta, Georgia, 30309
Northside Hospital Cancer Center
Atlanta, Georgia, 30342-1611
Saint Joseph's Hospital of Atlanta
Atlanta, Georgia, 30342-1701
CCOP - Atlanta Regional
Atlanta, Georgia, 30342
Sturdy Memorial Hospital
Attleboro, Massachusetts, 02703
Auburn Regional Center for Cancer Care
Auburn, Washington, 98002
Augusta Oncology Associates - Walton Way
Augusta, Georgia, 30901
Rush-Copley Cancer Care Center
Aurora, Illinois, 60507
WellStar Cobb Hospital
Austell, Georgia, 30106
CancerCare of Maine at Eastern Maine Medial Center
Bangor, Maine, 04401
Battle Creek Health System Cancer Care Center
Battle Creek, Michigan, 49017
St. Francis Hospital and Health Centers - Beech Grove Campus
Beech Grove, Indiana, 46107
St. Joseph Cancer Center
Bellingham, Washington, 98225
MeritCare Clinic - Bemidji
Bemidji, Minnesota, 56601
Hematology Oncology Associates of the Quad Cities
Bettendorf, Iowa, 52722
Study site
Bettendorf, Iowa, 52722
Mecosta County Medical Center
Big Rapids, Michigan, 49307
CCOP - Montana Cancer Consortium
Billings, Montana, 59101
Hematology-Oncology Centers of the Northern Rockies - Billings
Billings, Montana, 59101
Northern Rockies Radiation Oncology Center
Billings, Montana, 59101
St. Vincent Healthcare
Billings, Montana, 59101
Billings Clinic Cancer Center
Billings, Montana, 59107-5100
Deaconess Billings Clinic - Downtown
Billings, Montana, 59107-7000
Bismarck Cancer Center
Bismarck, North Dakota, 58501
Medcenter One Hospital Cancer Care Center
Bismarck, North Dakota, 58501
Mid Dakota Clinic, PC
Bismarck, North Dakota, 58501
St. Alexius Medical Center Cancer Center
Bismarck, North Dakota, 58502
Cancer Research Center at Boston Medical Center
Boston, Massachusetts, 02118
Wood County Oncology Center
Bowling Green, Ohio, 43402
Bozeman Deaconess Cancer Center
Bozeman, Montana, 59715
Olympic Hematology and Oncology
Bremerton, Washington, 98310
Veterans Affairs Medical Center - Buffalo
Buffalo, New York, 14215
Providence Saint Joseph Medical Center - Burbank
Burbank, California, 91505
Fairview Ridges Hospital
Burnsville, Minnesota, 55337
St. James Community Hospital
Butte, Montana, 59701
Mercy Cancer Center at Mercy Medical Center
Canton, Ohio, 44708
Saint Francis Medical Center
Cape Girardeau, Missouri, 63701
Southeast Missouri Regional Cancer Center at Southeast Missouri Hospital
Cape Girardeau, Missouri, 63701
St. Luke's Hospital
Cedar Rapids, Iowa, 52402
Cedar Rapids Oncology Associates
Cedar Rapids, Iowa, 52403
Mercy Regional Cancer Center at Mercy Medical Center
Cedar Rapids, Iowa, 52403
Providence Centralia Hospital Regional Cancer Center
Centralia, Washington, 98531-9027
Cancer Center of Kansas, PA - Chanute
Chanute, Kansas, 66720
Hollings Cancer Center at Medical University of South Carolina
Charleston, South Carolina, 29425
Martha Jefferson Hospital Cancer Care Center
Charlottesville, Virginia, 22901
Adena Regional Medical Center
Chillicothe, Ohio, 45601
Charles M. Barrett Cancer Center at University Hospital
Cincinnati, Ohio, 45267
MetroHealth's Cancer Care Center at MetroHealth Medical Center
Cleveland, Ohio, 44109
Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio, 44195
Finger Lakes Hematology and Oncology
Clifton Springs, New York, 14432
Memorial Hospital
Colorado Springs, Colorado, 80909
Veterans Affairs Medical Center - Columbia (Truman Memorial)
Columbia, Missouri, 65201
Ellis Fischel Cancer Center at University of Missouri - Columbia
Columbia, Missouri, 65203
Riverside Methodist Hospital Cancer Care
Columbus, Ohio, 43214-3998
CCOP - Columbus
Columbus, Ohio, 43215
Grant Riverside Cancer Services
Columbus, Ohio, 43215
Mount Carmel Health - West Hospital
Columbus, Ohio, 43222
Doctors Hospital at Ohio Health
Columbus, Ohio, 43228
Cancer Care Center at John Muir Health - Concord Campus
Concord, California, 94524-4110
Mercy and Unity Cancer Center at Mercy Hospital
Coon Rapids, Minnesota, 55433
Heartland Oncology & Hematology
Council Bluffs, Iowa, 51503
Medical City Dallas Hospital
Dallas, Texas, 75230
Geisinger Medical Center
Danville, Pennsylvania, 17822-0001
Danville Regional Medical Center
Danville, Virginia, 24541
Genesis Regional Cancer Center at Genesis Medical Center
Davenport, Iowa, 52803
Genesis Medical Center - West Campus
Davenport, Iowa, 52804
Grandview Hospital
Dayton, Ohio, 45405
Good Samaritan Hospital
Dayton, Ohio, 45406
Samaritan North Cancer Care Center
Dayton, Ohio, 45415
Veterans Affairs Medical Center - Dayton
Dayton, Ohio, 45428
CCOP - Dayton
Dayton, Ohio, 45429
Halifax Medical Center - Daytona Beach
Daytona Beach, Florida, 32115
Charles B. Eberhart Cancer Center at DeKalb Medical Center
Decatur, Georgia, 30033
Decatur Memorial Hospital Cancer Care Institute
Decatur, Illinois, 62526
Grady Memorial Hospital
Delaware, Ohio, 43015
Mercy Capitol Hospital
Des Moines, Iowa, 50307
CCOP - Iowa Oncology Research Association
Des Moines, Iowa, 50309
John Stoddard Cancer Center at Iowa Methodist Medical Center
Des Moines, Iowa, 50309
Medical Oncology and Hematology Associates at John Stoddard Cancer Center
Des Moines, Iowa, 50309
Medical Oncology and Hematology Associates at Mercy Cancer Center
Des Moines, Iowa, 50314
Mercy Cancer Center at Mercy Medical Center - Des Moines
Des Moines, Iowa, 50314
John Stoddard Cancer Center at Iowa Lutheran Hospital
Des Moines, Iowa, 50316-2301
Josephine Ford Cancer Center at Henry Ford Hospital
Detroit, Michigan, 48202
Cancer Center of Kansas, PA - Dodge City
Dodge City, Kansas, 67801
Oncology Hematology Associates of Northern Pennsylvania, PC at Hahne Regional Cancer Center
DuBois, Pennsylvania, 15801
Cancer Care Center at St. Luke's Hospital
Duluth, Minnesota, 55805
CCOP - Duluth
Duluth, Minnesota, 55805
Miller-Dwan Medical Center
Duluth, Minnesota, 55805
St. Mary's - Duluth Clinic Cancer Center
Duluth, Minnesota, 55805
Easton Regional Cancer Center at Easton Hospital
Easton, Pennsylvania, 18042
Fairview Southdale Hospital
Edina, Minnesota, 55435
Cancer Center of Kansas, PA - El Dorado
El Dorado, Kansas, 67042
Elkhart General Hospital
Elkhart, Indiana, 46515
Elmhurst Memorial Hospital
Elmhurst, Illinois, 60126
Green Bay Oncology, Limited - Escanaba
Escanaba, Michigan, 49431
Dakota Cancer Institute at Dakota Clinic - South University
Fargo, North Dakota, 58103
CCOP - MeritCare Hospital
Fargo, North Dakota, 58122
MeritCare Broadway
Fargo, North Dakota, 58122
St. Francis Hospital
Federal Way, Washington, 98003
Study site
Fergus Falls, Minnesota, 56537
Blanchard Valley Medical Associates
Findlay, Ohio, 45840
Hunterdon Regional Cancer Center at Hunterdon Medical Center
Flemington, New Jersey, 08822
Genesys Hurley Cancer Institute
Flint, Michigan, 48503
Hurley Medical Center
Flint, Michigan, 48503
Broward General Medical Center Cancer Center
Fort Lauderdale, Florida, 33316
Brooke Army Medical Center
Fort Sam Houston, Texas, 78234
Hembree Mercy Cancer Center at St. Edward Mercy Medical Center
Fort Smith, Arkansas, 72903
Washington Township Hospital
Fremont, California, 94538
Fremont Memorial Hospital
Fremont, Ohio, 43420
California Cancer Center - Woodward Park Office
Fresno, California, 93720
Mercy and Unity Cancer Center at Unity Hospital
Fridley, Minnesota, 55432
Adirondack Cancer Care - Glens Falls
Glens Falls, New York, 12801
Addison Gilbert Hospital
Gloucester, Massachusetts, 01930
Wayne Memorial Hospital, Incorporated
Goldsboro, North Carolina, 27534
CCOP - Grand Rapids
Grand Rapids, Michigan, 49503
Lacks Cancer Center at Saint Mary's Health Care
Grand Rapids, Michigan, 49503
Spectrum Health Hospital - Butterworth Campus
Grand Rapids, Michigan, 49503
Metro Health Hospital
Grand Rapids, Michigan, 49506
Big Sky Oncology
Great Falls, Montana, 59405
Great Falls Clinic
Great Falls, Montana, 59405
Sletten Regional Cancer Institute at Benefis Healthcare
Great Falls, Montana, 59405
Study site
Great Falls, Montana, 59405
Green Bay Oncology, Limited at St. Vincent Hospital
Green Bay, Wisconsin, 54301-3526
Green Bay Oncology, Limited at St. Mary's Hospital
Green Bay, Wisconsin, 54303
St. Mary's Hospital Medical Center - Green Bay
Green Bay, Wisconsin, 54303
St. Vincent Hospital Regional Cancer Center
Green Bay, Wisconsin, 54307-3508
Bon Secours St. Francis Health System
Greenville, South Carolina, 29601
CCOP - Greenville
Greenville, South Carolina, 29615
Van Elslander Cancer Center at St. John Hospital and Medical Center
Grosse Pointe Woods, Michigan, 48236
PinnacleHealth Regional Cancer Center at Polyclinic Hospital
Harrisburg, Pennsylvania, 17105
St. Peter's Hospital
Helena, Montana, 59601
Veterans Affairs Medical Center - Hines
Hines, Illinois, 60141
Holland Community Hospital
Holland, Michigan, 49423
Tripler Army Medical Center
Honolulu, Hawaii, 96859
Baylor University Medical Center - Houston
Houston, Texas, 77030
Ben Taub General Hospital
Houston, Texas, 77030
Methodist Hospital
Houston, Texas, 77030
St. Luke's Texas Cancer Institute at St. Luke's Episcopal Hospital
Houston, Texas, 77030
Veterans Affairs Medical Center - Houston
Houston, Texas, 77030
Huntsville Hospital
Huntsville, Alabama, 35801
Hutchinson Area Health Care
Hutchinson, Minnesota, 55350
Hematology Oncology Associates of Eastern Idaho
Idaho Falls, Idaho, 83404
Community Oncology Group at Cleveland Clinic Cancer Center
Independence, Ohio, 44131
Green Bay Oncology, Limited - Iron Mountain
Iron Mountain, Michigan, 49801
Foote Hospital
Jackson, Michigan, 49201
University of Mississippi Medical Center
Jackson, Mississippi, 39216
Mercy Regional Cancer Center
Janesville, Wisconsin, 53547
Capital Region Cancer Center
Jefferson City, Missouri, 65101
Joliet Oncology-Hematology Associates, Limited - West
Joliet, Illinois, 60435
Freeman Cancer Institute at Freeman Health System
Joplin, Missouri, 64804
Borgess Medical Center
Kalamazoo, Michigan, 49001
West Michigan Cancer Center
Kalamazoo, Michigan, 49007-3731
Bronson Methodist Hospital
Kalamazoo, Michigan, 49007
Glacier Oncology, PLLC
Kalispell, Montana, 59901
Kalispell Medical Oncology
Kalispell, Montana, 59901
Kalispell Regional Medical Center
Kalispell, Montana, 59901
Veterans Affairs Medical Center - Kansas City
Kansas City, Kansas, 64128
CCOP - Kansas City
Kansas City, Missouri, 64131
Good Samaritan Cancer Center at Good Samaritan Hospital
Kearney, Nebraska, 68848-1990
Kenton Oncology, Incorporated
Kenton, Ohio, 43326
Charles F. Kettering Memorial Hospital
Kettering, Ohio, 45429
Cancer Center of Kansas, PA - Kingman
Kingman, Kansas, 67068
Lenoir Memorial Cancer Center
Kinston, North Carolina, 28501
Merle West Medical Center Cancer Treatment Center
Klamath Falls, Oregon, 97601
Thompson Cancer Survival Center
Knoxville, Tennessee, 37916
U.T. Cancer Institute at University of Tennessee Medical Center
Knoxville, Tennessee, 37920-6999
Howard Community Hospital at Howard Regional Health System
Kokomo, Indiana, 46904
Gundersen Lutheran Cancer Center at Gundersen Lutheran Medical Center
La Crosse, Wisconsin, 54601
La Grange Memorial Hospital
La Grange, Illinois, 60525
Center for Cancer Therapy at LaPorte Hospital and Health Services
La Porte, Indiana, 46350
Wilford Hall Medical Center
Lackland Air Force Base, Texas, 78236
Fairfield Medical Center
Lancaster, Ohio, 43130
Lancaster General Hospital
Lancaster, Pennsylvania, 17604
St. Mary Regional Cancer Center
Langhorne, Pennsylvania, 19047
Sparrow Regional Cancer Center
Lansing, Michigan, 48909
University Medical Center of Southern Nevada
Las Vegas, Nevada, 89102
CCOP - Nevada Cancer Research Foundation
Las Vegas, Nevada, 89106
Gwinnett Medical Center
Lawrenceville, Georgia, 30045
Southwest Medical Center
Liberal, Kansas, 67901
St. Rita's Medical Center
Lima, Ohio, 45801
Lima Memorial Hospital
Lima, Ohio, 45804
Cancer Resource Center - Lincoln
Lincoln, Nebraska, 68510
Meeker County Memorial Hospital
Litchfield, Minnesota, 55355
Arkansas Cancer Research Center at University of Arkansas for Medical Sciences
Little Rock, Arkansas, 72205
Logan Regional Hospital
Logan, Utah, 84321
USC/Norris Comprehensive Cancer Center and Hospital
Los Angeles, California, 90089-9181
UMC Southwest Cancer and Research Center
Lubbock, Texas, 79415-3364
Lynchburg Hematology-Oncology Clinic
Lynchburg, Virginia, 24501
Merle M. Mahr Cancer Center at Regional Medical Center of Hopkins County
Madisonville, Kentucky, 42431
CCOP - North Shore University Hospital
Manhasset, New York, 11030
Don Monti Comprehensive Cancer Center at North Shore University Hospital
Manhasset, New York, 11030
Holy Family Memorial Medical Center Cancer Care Center
Manitowoc, Wisconsin, 54221-1450
Immanuel St. Joseph's Clinic
Mankato, Minnesota, 56002
MedCentral - Mansfield Hospital
Mansfield, Ohio, 44903
HealthEast Cancer Care at St. John's Hospital
Maplewood, Minnesota, 55109
Minnesota Oncology Hematology, PA at Maplewood Cancer Center
Maplewood, Minnesota, 55109
Kennestone Cancer Center at Wellstar Kennestone Hospital
Marietta, Georgia, 30060
Strecker Cancer Center at Marietta Memorial Hospital
Marietta, Ohio, 45750
Bay Area Cancer Care Center at Bay Area Medical Center
Marinette, Wisconsin, 54143
Upper Michigan Cancer Center at Marquette General Hospital
Marquette, Michigan, 49855
Marshfield Clinic - Marshfield Center
Marshfield, Wisconsin, 54449
Mercy Cancer Center at Mercy Medical Center - North Iowa
Mason City, Iowa, 50401
St. Luke's Hospital
Maumee, Ohio, 43537
Northwest Ohio Oncology Center
Maumee, Ohio, 43623
Cardinal Bernardin Cancer Center at Loyola University Medical Center
Maywood, Illinois, 60153
University of Tennessee Cancer Institute - Medical Center
Memphis, Tennessee, 38104
Saint Anthony Memorial Health Centers
Michigan City, Indiana, 46360
Tucker Center for Cancer Care at Orange Regional Medical Center
Middletown, New York, 10940-4199
Middletown Regional Hospital
Middletown, Ohio, 45044
MidMichigan Medical Center - Midland
Midland, Michigan, 48670
Winthrop University Hospital
Mineola, New York, 11501
Virginia Piper Cancer Institute at Abbott-Northwestern Hospital
Minneapolis, Minnesota, 55407
Hennepin County Medical Center - Minneapolis
Minneapolis, Minnesota, 55415
Community Medical Center
Missoula, Montana, 59801
Guardian Oncology and Center for Wellness
Missoula, Montana, 59804
Montana Cancer Specialists at Montana Cancer Center
Missoula, Montana, 59807-7877
Montana Cancer Center at St. Patrick Hospital and Health Sciences Center
Missoula, Montana, 59807
Mobile Infirmary Medical Center
Mobile, Alabama, 36652-2144
Trinity Medical Center - East
Moline, Illinois, 61265
Study site
Moline, Illinois, 61265
Louisiana State University Health Sciences Center - Monroe
Monroe, Louisiana, 71210
Community Cancer Center of Monroe
Monroe, Michigan, 48162
Mercy Memorial Hospital System
Monroe, Michigan, 48162
Chippewa County - Montevideo Hospital
Montevideo, Minnesota, 56265
Carol G. Simon Cancer Center at Morristown Memorial Hospital
Morristown, New Jersey, 07962
Ted B. Wahby Cancer Center at Mount Clemens General Hospital
Mount Clemens, Michigan, 48043
Good Samaritan Regional Health Center
Mount Vernon, Illinois, 62864
Skagit Valley Hospital Cancer Care Center
Mount Vernon, Washington, 98273
Cottonwood Hospital Medical Center
Murray, Utah, 84107
Hackley Hospital
Muskegon, Michigan, 49442
Jersey Shore Cancer Center at Jersey Shore University Medical Center
Neptune City, New Jersey, 07754-0397
Long Island Jewish Medical Center
New Hyde Park, New York, 11042
Licking Memorial Cancer Care Program at Licking Memorial Hospital
Newark, Ohio, 43055
Peninsula Cancer Institute - Newport News Office
Newport News, Virginia, 23601
Cancer Center of Kansas, PA - Newton
Newton, Kansas, 67114
Eastern Connecticut Hematology and Oncology Associates
Norwich, Connecticut, 06360
Green Bay Oncology, Limited - Oconto Falls
Oconto Falls, Wisconsin, 54154
McKay-Dee Hospital Center
Ogden, Utah, 84403
Providence St. Peter Hospital Regional Cancer Center
Olympia, Washington, 98506-5166
CCOP - Missouri Valley Cancer Consortium
Omaha, Nebraska, 68106
Methodist Cancer Center at Methodist Hospital - Omaha
Omaha, Nebraska, 68114
Immanuel Medical Center
Omaha, Nebraska, 68122
Alegant Health Cancer Center at Bergan Mercy Medical Center
Omaha, Nebraska, 68124
Creighton University Medical Center
Omaha, Nebraska, 68131-2197
East Alabama Medical Center
Opelika, Alabama, 36801-5452
St. Charles Mercy Hospital
Oregon, Ohio, 43616
Toledo Clinic - Oregon
Oregon, Ohio, 43616
McCreery Cancer Center at Ottumwa Regional
Ottumwa, Iowa, 52501
Desert Regional Medical Center Comprehensive Cancer Center
Palm Springs, California, 92262
Cancer Center of Kansas, PA - Parsons
Parsons, Kansas, 67357
West Florida Cancer Institute at West Florida Hospital - Pensacola
Pensacola, Florida, 32514
Northern Michigan Hospital
Petoskey, Michigan, 49770
Allegheny Cancer Center at Allegheny General Hospital
Pittsburgh, Pennsylvania, 15212
Mercy Regional Cancer Center at Mercy Hospital
Port Huron, Michigan, 48060
Veterans Affairs Medical Center - Portland
Portland, Oregon, 97207
Kaiser Permanente Health Care - Portland
Portland, Oregon, 97232
Oregon Health & Science University Cancer Institute
Portland, Oregon, 97239-3098
Cancer Center of Kansas, PA - Pratt
Pratt, Kansas, 67124
Utah Valley Regional Medical Center - Provo
Provo, Utah, 84604
Good Samaritan Cancer Center
Puyallup, Washington, 98372
All Saints Cancer Center at Wheaton Franciscan Healthcare
Racine, Wisconsin, 53405
Rapid City Regional Hospital
Rapid City, South Dakota, 57701
Shasta Regional Medical Center
Redding, California, 96001
Marshfield Clinic - Indianhead Center
Rice Lake, Wisconsin, 54868
Reid Hospital & Health Care Services, Incorporated
Richmond, Indiana, 47374
Veterans Affairs Medical Center - Richmond
Richmond, Virginia, 23249
West Suburban Center for Cancer Care
River Forest, Illinois, 60305
Southern Regional Medical Center
Riverdale, Georgia, 30274-2600
Hubert H. Humphrey Cancer Center at North Memorial Medical Center
Robbinsdale, Minnesota, 55422-2900
Mayo Clinic Cancer Center
Rochester, Minnesota, 55905
Interlakes Oncology/Hematology PC
Rochester, New York, 14623
James P. Wilmot Cancer Center at University of Rochester Medical Center
Rochester, New York, 14642
Swedish-American Regional Cancer Center
Rockford, Illinois, 61104-2315
Sutter Cancer Center at Roseville Medical Center
Roseville, California, 95661
Rutherford Hospital
Rutherfordton, North Carolina, 28139
Sutter Cancer Center
Sacramento, California, 95816
University of California Davis Cancer Center
Sacramento, California, 95817
Seton Cancer Institute - Saginaw
Saginaw, Michigan, 48601
CentraCare Clinic - River Campus
Saint Cloud, Minnesota, 56303
Coborn Cancer Center
Saint Cloud, Minnesota, 56303
Lakeland Cancer Care Center at Lakeland Hospital - St. Joseph
Saint Joseph, Michigan, 49085
CCOP - Metro-Minnesota
Saint Louis Park, Minnesota, 55416
Park Nicollet Health Services
Saint Louis Park, Minnesota, 55416
Regions Hospital Cancer Care Center
Saint Paul, Minnesota, 55101
St. Joseph's Hospital
Saint Paul, Minnesota, 55102
United Hospital
Saint Paul, Minnesota, 55102
Salem Hospital Regional Cancer Care Services
Salem, Oregon, 97309-5014
Canada2 sites
Allan Blair Cancer Centre at Pasqua Hospital
Regina, Saskatchewan, S4T 7T1
Saskatoon Cancer Centre at the University of Saskatchewan
Saskatoon, Saskatchewan, S7N 4H4
About this study
Official title: Randomized Phase III Trial of Cisplatin and Irinotecan (NSC-616348) Versus Cisplatin and Etoposide in Patients With Extensive Stage Small Cell Lung Cancer (E-SCLC)
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known whether cisplatin combined with irinotecan is more effective than cisplatin combined with etoposide in treating extensive-stage small cell lung cancer.
PURPOSE: Randomized phase III trial to compare the effectiveness of cisplatin combined with either irinotecan or etoposide in treating patients who have extensive-stage small cell lung cancer.
Read the detailed description
OBJECTIVES:
- Compare the survival of patients with extensive stage small cell lung cancer treated with cisplatin and irinotecan vs cisplatin and etoposide.
- Compare the objective response rate and progression-free survival of patients treated with these regimens.
- Compare the toxic effects of these regimens in these patients.
- Determine the association between UGT1A1 polymorphisms and irinotecan-associated toxic effects in these patients.
- Determine the association between ERCC-1 and XRCC-1 polymorphisms and non-response of patients treated with these regimens.
OUTLINE: This is a randomized, multicenter study. Patients are stratified according to number of metastatic sites (single vs multiple), lactic dehydrogenase (no greater than upper limit of normal (ULN) vs greater than ULN), and weight loss in the past 6 months (5% or less vs more than 5%). Patients are randomized to 1 of 2 treatment arms.
- Arm I: Patients receive irinotecan IV over 90 minutes on days 1, 8, and 15 and cisplatin IV over 30-60 minutes on day 1. Courses repeat every 4 weeks.
- Arm II: Patients receive etoposide IV over 30-60 minutes on days 1-3 and cisplatin IV over 30-60 minutes on day 1. Courses repeat every 3 weeks.
Treatment in both arms continues for 4 courses in the absence of disease progression or unacceptable toxicity.
Patients are followed every 3 months for 1 year and then every 6 months for 2 years.
PROJECTED ACCRUAL: A total of 620 patients (310 per treatment arm) will be accrued for this study within 4 years.
- Conditions
- Lung Cancer
- Being tested
- cisplatin, etoposide, irinotecan hydrochloride
- Keywords
- extensive stage small cell lung cancer
- Medical subject headings
- Lung Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
cisplatinDrug
Arm 1: 60 mg/m2 IV (over 30-60 min) on Day 1, Q 4 weeks x 4 Cycles
Arm 2: 80 mg/m2 IV (over 30-60 min) on Day 1, Q 4 weeks x 4 Cycles
etoposideDrug
100 mg/m2 IV (over 30-60 min) on Days 1 , 2 \& 3. Q 3 weeks x 4 Cycles
60 mg/m2 IV (over 90 min)on Days 1, 8 \& 15. Q 4 weeks x 4 Cycles
| Study group | Role | What they receive |
|---|---|---|
| 1 | Active comparator | Not described Receives: Drug: cisplatin; Drug: irinotecan hydrochloride |
| 2 | Active comparator | Not described Receives: Drug: cisplatin; Drug: etoposide |
What is being measured
The primary outcome is the main question the study is designed to answer.
Overall Survival
Overall survival was defined as the duration between the date of randomization( enrollment) and the date of death due to any cause. Patients last known to be alive were censored at the date of last contact.
Measured: Weekly while on treatment, then every 3 months for first year, then every 6 months unitl a maximum of 3 years from enrollment.
Secondary outcomes (3)
Progression-free Survival
Progression-Free Survival was defined as the duration from the date of randomization (enrollment) until the date of documentation of progression as defined by RECIST (a 20% increase over nadir in the sum of longest diameters of target lesions, clear progression of a non-target lesion in the opinion of the treating investigator, appearance of new lesions, or symptomatic deterioration) or death due to any cause. Patients last known to be alive and without evidence of progression were censored at the date of last contact.
Measured: Every 6 weeks until disease progression or a maximum of 3 years from the date of enrollment.
Confirmed and Unconfirmed Complete and Partial Responses.
Patients underwent chest CT/MRI every 6 weeks while on treatment and tumor response was evaluated by RECIST in the subset of patients with at least one target lesion at baseline. A target lesion was defined as a lesion with a longest diameter of at least 2 cm ( or at least 1 cm if by spiral CT). A complete response (CR) was defined as the disappearance of all disease, including non-target lesions. A partial response (PR) was defined as a 30% or greater decrease in the sum of the longest diameters. Confirmation of a CR or PR was defined as a second determination of CR or PR at least 4 weeks after the first determination.
Measured: Every 6 weeks while on protocol treatment for a maximum of 12 weeks
Number of Patients With a Given Type and Grade of Adverse Event.
Only adverse events that are possibly, probably or definitely related to study drug are reported. Only patients who received protocol treatment and were assessed for adverse events are included.
Measured: Every 4 weeks while subject on protocol treatment for a maximum of 12 weeks.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Jan 2003 (estimated)
- Study startNov 2002
- Primary completionMar 2008
- Study completionDec 2009
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (4)Papers the sponsor has linked to this study.
- Other trials for Lung CancerStudies of the same condition, open and under way.
- More trials run by SWOG Cancer Research NetworkThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 671 participants (actual)
Sponsor and investigators
- Lead sponsor
- SWOG Cancer Research Network
- Sponsor type
- Research network
- Collaborators
- National Cancer Institute (NCI), North Central Cancer Treatment Group, Cancer and Leukemia Group B
- Responsible party
- Sponsor
- Investigators
- Ronald B. Natale, MD, Principal investigator, Cedars-Sinai Medical CenterDavid R. Gandara, MD, Principal investigator, University of California, DavisPrimo N. Lara, MD, Principal investigator, University of California, DavisJames R. Jett, MD, Principal investigator, Mayo ClinicJane Carleton, MD, Principal investigator, Don Monti Comprehensive Cancer Center at North Shore University Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00045162
- Sponsor's protocol ID
- CDR0000256908
- Other IDs
- S0124, S0124, S0124, U10CA032102
- Status last verified
- Jul 2018
- First submitted
- 6 Sep 2002
- Last updated
- 31 Jul 2018
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
Publications
Lara P, Chansky K, Shibata T, et al.: Cisplatin + irinotecan versus cisplatin + etoposide in extensive stage small cell lung cancer (E-SCLC): Final "common arm": comparative outcomes analysis of JCOG 9511 and SWOG 0124. [Abstract] J Clin Oncol 27 (Suppl 15): A-8027, 2009.
Lara PN Jr, Natale R, Crowley J, Lenz HJ, Redman MW, Carleton JE, Jett J, Langer CJ, Kuebler JP, Dakhil SR, Chansky K, Gandara DR. Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol. 2009 May 20;27(15):2530-5. doi: 10.1200/JCO.2008.20.1061. Epub 2009 Apr 6.
PubMed 19349543Natale RB, Lara PN, Chansky K, et al.: S0124: A randomized phase III trial comparing irinotecan/cisplatin (IP) with etoposide/cisplatin (EP) in patients (pts) with previously untreated extensive stage small cell lung cancer (E-SCLC). [Abstract] J Clin Oncol 26 (Suppl 15): A-7512, 2008.
Hanna N, Bunn PA Jr, Langer C, Einhorn L, Guthrie T Jr, Beck T, Ansari R, Ellis P, Byrne M, Morrison M, Hariharan S, Wang B, Sandler A. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol. 2006 May 1;24(13):2038-43. doi: 10.1200/JCO.2005.04.8595.
PubMed 16648503
Study at a glance
From the registry record, last updated by the sponsor on 31 Jul 2018. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Randomized Phase III Trial of Cisplatin and Irinotecan (NSC-616348) Versus Cisplatin and Etoposide in Patients With Extensive Stage Small Cell Lung Cancer (E-SCLC)
- ClinicalTrials.gov ID
- NCT00045162
- Acronym / sponsor ID
- CDR0000256908
- Conditions
- Lung Cancer
- Keywords
- extensive stage small cell lung cancer
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 671 participants (actual)
- Lead sponsor
- SWOG Cancer Research NetworkResearch network
- Collaborators
- National Cancer Institute (NCI), North Central Cancer Treatment Group, Cancer and Leukemia Group B
- Study start
- Nov 2002
- Primary completion
- Mar 2008 (actual)
- Study completion
- Dec 2009 (actual)
- First posted
- 27 Jan 2003 (estimated)
- Results
- Posted 9 Jul 2013
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known whether cisplatin combined with irinotecan is more effective than cisplatin combined with etoposide in treating extensive-stage small cell lung cancer.
PURPOSE: Randomized phase III trial to compare the effectiveness of cisplatin combined with either irinotecan or etoposide in treating patients who have extensive-stage small cell lung cancer.
Detailed description
OBJECTIVES:
- Compare the survival of patients with extensive stage small cell lung cancer treated with cisplatin and irinotecan vs cisplatin and etoposide.
- Compare the objective response rate and progression-free survival of patients treated with these regimens.
- Compare the toxic effects of these regimens in these patients.
- Determine the association between UGT1A1 polymorphisms and irinotecan-associated toxic effects in these patients.
- Determine the association between ERCC-1 and XRCC-1 polymorphisms and non-response of patients treated with these regimens.
OUTLINE: This is a randomized, multicenter study. Patients are stratified according to number of metastatic sites (single vs multiple), lactic dehydrogenase (no greater than upper limit of normal (ULN) vs greater than ULN), and weight loss in the past 6 months (5% or less vs more than 5%). Patients are randomized to 1 of 2 treatment arms.
- Arm I: Patients receive irinotecan IV over 90 minutes on days 1, 8, and 15 and cisplatin IV over 30-60 minutes on day 1. Courses repeat every 4 weeks.
- Arm II: Patients receive etoposide IV over 30-60 minutes on days 1-3 and cisplatin IV over 30-60 minutes on day 1. Courses repeat every 3 weeks.
Treatment in both arms continues for 4 courses in the absence of disease progression or unacceptable toxicity.
Patients are followed every 3 months for 1 year and then every 6 months for 2 years.
PROJECTED ACCRUAL: A total of 620 patients (310 per treatment arm) will be accrued for this study within 4 years.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| 1 | Active comparator | Drug: cisplatin, Drug: irinotecan hydrochloride |
| 2 | Active comparator | Drug: cisplatin, Drug: etoposide |
Who may qualify
- Ages
- 18 to 120 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| cisplatinArm 1: 60 mg/m2 IV (over 30-60 min) on Day 1, Q 4 weeks x 4 Cycles Arm 2: 80 mg/m2 IV (over 30-60 min) on Day 1, Q 4 weeks x 4 Cycles | Drug | 1, 2 |
| etoposide100 mg/m2 IV (over 30-60 min) on Days 1 , 2 \& 3. Q 3 weeks x 4 Cycles | Drug | 2 |
| irinotecan hydrochloride60 mg/m2 IV (over 90 min)on Days 1, 8 \& 15. Q 4 weeks x 4 Cycles | Drug | 1 |
Primary outcome
Overall Survival
Time frame: Weekly while on treatment, then every 3 months for first year, then every 6 months unitl a maximum of 3 years from enrollment.
Overall survival was defined as the duration between the date of randomization( enrollment) and the date of death due to any cause. Patients last known to be alive were censored at the date of last contact.
3 secondary outcomes
Progression-free Survival
Time frame: Every 6 weeks until disease progression or a maximum of 3 years from the date of enrollment.
Confirmed and Unconfirmed Complete and Partial Responses.
Time frame: Every 6 weeks while on protocol treatment for a maximum of 12 weeks
Number of Patients With a Given Type and Grade of Adverse Event.
Time frame: Every 4 weeks while subject on protocol treatment for a maximum of 12 weeks.
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 31 Jul 2018.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- BackgroundLara P, Chansky K, Shibata T, et al.: Cisplatin + irinotecan versus cisplatin + etoposide in extensive stage small cell lung cancer (E-SCLC): Final "common arm": comparative outcomes analysis of JCOG 9511 and SWOG 0124. [Abstract] J Clin Oncol 27 (Suppl 15): A-8027, 2009.
- Results publication: PubMed 19349543Lara PN Jr, Natale R, Crowley J, Lenz HJ, Redman MW, Carleton JE, Jett J, Langer CJ, Kuebler JP, Dakhil SR, Chansky K, Gandara DR. Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol. 2009 May 20;27(15):2530-5. doi: 10.1200/JCO.2008.20.1061. Epub 2009 Apr 6.
- Results publicationNatale RB, Lara PN, Chansky K, et al.: S0124: A randomized phase III trial comparing irinotecan/cisplatin (IP) with etoposide/cisplatin (EP) in patients (pts) with previously untreated extensive stage small cell lung cancer (E-SCLC). [Abstract] J Clin Oncol 26 (Suppl 15): A-7512, 2008.
- Results publication: PubMed 16648503Hanna N, Bunn PA Jr, Langer C, Einhorn L, Guthrie T Jr, Beck T, Ansari R, Ellis P, Byrne M, Morrison M, Hariharan S, Wang B, Sandler A. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol. 2006 May 1;24(13):2038-43. doi: 10.1200/JCO.2005.04.8595.
Related trials for Lung Cancer
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
RecruitingObservational study
A Prospective ,Multicenter ,Non-interventional ,Real-world Study Observing Changes in Molecular Markers Osimertinib Targeted Therapy in EGFRm NSCLC
Non Small Cell Lung Cancer
Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
RecruitingPhase 3
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Non-Small Cell Lung Cancer (NSCLC)
Active, not recruitingPhase 2
Datopotamab Deruxtecan (Dato-DXd, DS-1062a) in Advanced and/or Unresectable Non-Small Cell Lung Cancer
Metastatic Lung Cancer, Advanced Non Small Cell Lung Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Ronald B. Natale, MD principal investigator
Cedars-Sinai Medical Center
David R. Gandara, MD principal investigator
University of California, Davis
Primo N. Lara, MD principal investigator
University of California, Davis
408 sites in 2 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing cisplatin, etoposide and irinotecan hydrochloride in people with Lung Cancer, run by SWOG Cancer Research Network at 408 sites in 2 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 31 Jul 2018. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 408 sites in United States, Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 9 Jul 2013). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Overall Survival (time frame: Weekly while on treatment, then every 3 months for first year, then every 6 months unitl a maximum of 3 years from enrollment.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT00045162, which also lists 4 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 31 Jul 2018.